This article was originally published in The Gray Sheet
Donald Brounstein resigns as president and CEO of the Cranford, New Jersey firm May 19. Since founding the company in 1995, Brounstein managed the development and recent launch of the firm's Breast Alert breast cancer detection device ("The Gray Sheet" Nov. 17, In Brief). Elizabeth Tallett replaces Brounstein on an interim basis as chairman and acting CEO until a permanent replacement is found. Tallett maintains responsibilities as president and CEO of two start-up companies: Dioscor, a biotech management company and Ellard Pharmaceuticals...
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.